Dr. Morgensztern is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4921 Parkview Pl
Fl 7
Saint Louis, MO 63110Phone+1 314-747-1171Fax+1 314-362-3192- Is this information wrong?
Education & Training
- University of Miami/Jackson Health SystemResidency, Internal Medicine, 1998 - 2001
- Tech- Ed Fndn Souza Marques Sch MedClass of 1995
Certifications & Licensure
- MO State Medical License 2013 - 2025
- CT State Medical License 2010 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction Start of enrollment: 2007 Mar 01
- Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
- Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16
- Join now to see all
Publications & Presentations
PubMed
- 96 citationsRecurrent WNT pathway alterations are frequent in relapsed small cell lung cancerAlex H. Wagner, Siddhartha Devarakonda, Zachary L. Skidmore, Kilannin Krysiak, Avinash Ramu
Nature Communications. 2018-09-17 - 2660 citationsThe biology and management of non-small cell lung cancerRoy S. Herbst, Daniel Morgensztern, Chris Boshoff
Nature. 2018-01-24 - 1360 citationsChanging Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseRamaswamy Govindan, Nathan C. Page, Daniel Morgensztern, William L. Read, Ryan M. Tierney
Journal of Clinical Oncology. 2006-10-01
Journal Articles
- Recurrent WNT Pathway Alterations Are Frequent in Relapsed Small Cell Lung CancerSaiama N. Waqar, Daniel Morgensztern, Robert S. Fulton, Ramaswamy Govindan, Nature
Lectures
- Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure.2019 ASCO Annual Meeting - 6/1/2019
- Multicenter phase II trial of RRx-001 in previously treated SCLC.2019 ASCO Annual Meeting - 6/1/2019
- Yale Cancer Center Evening Oncology Series: Lung CancerYale CME, New Haven, Connecticut - 5/10/2012
Authored Content
- Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small-Cell Lung CancerFebruary 2018
Press Mentions
- Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung CancerMarch 10th, 2021
- Adding a Vaccine to Immunotherapy in Lung Cancer: Will It Improve Outcomes?March 4th, 2019
- Heat Biologics, Inc. (NASDAQ:HTBX) Files an 8-K Regulation FD DisclosureFebruary 28th, 2019
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Barnes-Jewish HospitalSaint Louis, Missouri
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: